NEW HAVEN, Conn., October 7, 2013 – Melinta Therapeutics today announced the appointment of Lyn Baranowski as senior vice president, corporate development and strategy. In this role, Baranowski is responsible for structuring, negotiating and executing successful strategic alliances, licensing agreements, M&A transactions, and financial investments, as well as providing business development, management and strategic leadership to the organization. She is a member of the executive leadership team.
“Lyn brings to Melinta valuable pharmaceutical corporate development skills, exemplified by her recent success at Pearl Therapeutics. In addition, her experience with both the private and public investment communities will yield valuable insights,” said Mary Szela, chief executive officer of Melinta Therapeutics. “These skills, paired with her ability to think strategically about a company’s short- and long-term corporate development, will be critical as we move forward. I believe that Lyn’s addition to the team brings us one step closer to meeting our goal of bringing urgently-needed antibiotics to the global healthcare market.”
Baranowski brings to Melinta Therapeutics broad and deep life sciences industry experience spanning biotech, pharmaceuticals and venture capital. Previously, Baranowski was vice president of commercial development at Pearl Therapeutics and was instrumental in driving the company’s corporate development activities including its recent sale to AstraZeneca for $1.15 billion. Before her role at Pearl Therapeutics, Baranowski served as vice president of Vatera Healthcare Partners, a healthcare-focused venture capital firm based in New York where she was responsible for lead identification, evaluation, and negotiation as well as working with management teams of portfolio companies to develop and implement business plans. Baranowski previously held public affairs, business development and commercial executive roles at Novartis, including leading the launch of the osteoporosis drug Reclast®.
Baranowski holds a B.A. from American University and an M.B.A. from Harvard Business School.
Melinta Therapeutics, based on the application of Nobel Prize-winning science, is dedicated to the discovery, development and commercialization of groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). A key initiative at Melinta is to develop a new class of antibiotics designed to overcome the drug-resistant ESKAPE pathogens known to cause serious hospital infections. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus. The company is headquartered in New Haven, CT with offices in Lincolnshire, IL.
For more information, visit www.melinta.com